Curon Stretta
This article was originally published in The Gray Sheet
Executive Summary
Voluntary recall of all affected lots of the catheters for treatment of gastroesophageal reflux disease (GERD) is complete, Curon announces Jan. 5. A "manufacturing irregularity" related to 278 catheters "has been identified, and we have resumed normal manufacturing processes," Curon says. The firm does not expect "a major impact" on 2001 fiscal year results, according to President and CEO John Morgan. The device received 510(k) clearance in April (1"The Gray Sheet" Oct. 2, 2000, p. 16)
You may also be interested in...
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.